Cannabinoid-sensitive receptors in cardiac physiology and ischaemia
- PMID: 30890410
- DOI: 10.1016/j.bbamcr.2019.03.009
Cannabinoid-sensitive receptors in cardiac physiology and ischaemia
Abstract
The classical cannabinoid receptors CB1 and CB2 as well as the cannabinoid-sensitive receptor GPR55 are widely distributed throughout the mammalian body. In the cardiovascular field, CB1 and CB2 crucially impact on diseases characterized by inflammatory processes, such as atherosclerosis and acute myocardial infarction. Both receptors and their endogenous ligands anandamide and 2-arachidonoylglycerol are up-regulated in the ischaemic heart in humans and animal models. Pharmacological and genetic interventions with CB1 and CB2 vitally affect acute ischaemia-induced cardiac inflammation. Herein, CB1 rather aggravates the inflammatory response whereas CB2 mitigates inflammation via directly affecting immune cell attraction, macrophage polarization and lymphocyte clusters in the pericardial adipose tissue. Furthermore, cannabinoids and their receptors affect numerous cardiac risk factors. In this context, cannabis consumption is debated to trigger arrhythmias and even myocardial infarction. Moreover, CB1 activation is linked to impaired lipid and glucose metabolism and therefore obesity and diabetes, while its antagonism leads to the reduction of plasma triglycerides, low-density lipoprotein cholesterol, leptin, insulin and glucose. On the other hand, activation of cannabinoid-sensitive receptors can also counteract unfavourable predictors for cardiovascular diseases. In particular, hypertension can be mitigated via CB1 agonism and impaired adrenoceptor responsiveness prevented by functional GPR55. Taken together, current insights identify the cannabinoid system as promising target not only to therapeutically interfere with the vasculature, but also to affect the heart as target organ. This review discusses current knowledge regarding a direct cardiac role of the cannabinoid system and points out its feasible therapeutic manipulation in the ischaemic myocardium.
Keywords: CB1; CB2; Cannabinoids; GPR55; Ischaemia/reperfusion; Marijuana; Myocardial infarction.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors.Br J Pharmacol. 2020 Apr;177(8):1865-1880. doi: 10.1111/bph.14958. Epub 2020 Feb 11. Br J Pharmacol. 2020. PMID: 31877572 Free PMC article.
-
CB2 Cannabinoid Receptor as a Potential Target in Myocardial Infarction: Exploration of Molecular Pathogenesis and Therapeutic Strategies.Int J Mol Sci. 2024 Jan 30;25(3):1683. doi: 10.3390/ijms25031683. Int J Mol Sci. 2024. PMID: 38338960 Free PMC article. Review.
-
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.J Cell Physiol. 2022 Sep;237(9):3517-3540. doi: 10.1002/jcp.30837. Epub 2022 Jul 21. J Cell Physiol. 2022. PMID: 35862111 Review.
-
Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists.J Cardiovasc Pharmacol Ther. 2016 May;21(3):262-72. doi: 10.1177/1074248415612593. Epub 2015 Oct 19. J Cardiovasc Pharmacol Ther. 2016. PMID: 26487546 Review.
-
CB1 and CB2 receptors differentially modulate the cognitive impact of maternal immune activation and perinatal cannabinoid exposure.Behav Brain Res. 2025 May 8;485:115543. doi: 10.1016/j.bbr.2025.115543. Epub 2025 Mar 18. Behav Brain Res. 2025. PMID: 40113177
Cited by
-
Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension.Front Pharmacol. 2022 Sep 2;13:965613. doi: 10.3389/fphar.2022.965613. eCollection 2022. Front Pharmacol. 2022. PMID: 36120288 Free PMC article.
-
Cannabinoid Receptors in Myocardial Injury: A Brother Born to Rival.Int J Mol Sci. 2021 Jun 26;22(13):6886. doi: 10.3390/ijms22136886. Int J Mol Sci. 2021. PMID: 34206926 Free PMC article. Review.
-
Pharmacokinetic/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers.Eur J Drug Metab Pharmacokinet. 2025 May;50(3):229-242. doi: 10.1007/s13318-025-00941-8. Epub 2025 Apr 5. Eur J Drug Metab Pharmacokinet. 2025. PMID: 40186795 Free PMC article.
-
Adverse Effects of Cannabinoids and Tobacco Consumption on the Cardiovascular System: A Systematic Review.Cureus. 2022 Sep 15;14(9):e29208. doi: 10.7759/cureus.29208. eCollection 2022 Sep. Cureus. 2022. PMID: 36159363 Free PMC article. Review.
-
Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs of Rats with Monocrotaline-Induced Pulmonary Hypertension.Molecules. 2022 May 22;27(10):3327. doi: 10.3390/molecules27103327. Molecules. 2022. PMID: 35630804 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources